| Background:Adiponectin(APN)is an endogenous bioactive peptide secreted by adipose tissue,which can promote lipolysis and has anti-inflammatory and anti-atherosclerotic properties in vivo.The role of rs266729(C>G)polymorphism in promoter and rs2241766 polymorphism in exon of APN gene in coronary heart disease(CAD)has been widely reported,but the results were inconsistent.In addition,whether the two polymorphic sites are related to the severity of CAD has not been reported.Objective:To explore the relationships between the rs266729 and rs2241766 polymorphisms of APN gene and risk factors,susceptibility and severity of CAD,and to provide experimental basis for the explanation of genetic mechanisms and accurate diagnosis and treatment for CAD.Methods:A total of 649 hospitalized patients with suspected CAD who underwent coronary angiography were randomly selected as the research objects.According to the results of coronary angiography,the subjects were divided into CAD group(433 cases)and control group(216 cases).The clinical data of all subjects were collected,including general situation,physiological indexes,biochemical indexes,etc.Genomic DNA of peripheral blood leukocytes was extracted,and the rs266729 and rs2241766 polymorphisms of APN gene were genotyped by polymerase chain reaction-restriction fragment length polymorphism(PCR-RFLP).The severity of CAD was evaluated by Gensini scoring system,the degree of coronary artery stenosis and the number of coronary artery lesions.Meta-analysis on the association of APN gene rs266729 polymorphism with APN levels and CAD risk factors.Results:The atherogenic risk factors such as age,smoking rate,hypertension,diabetes mellitus,low density lipoprotein cholesterol(LDL-C),apoliprotein(APOB),lipoprotein a[Lp(a)],blood glucose,Cystatin C(CysC)and hypersensitive C-reactive protein(hs-CRP)were significantly higher,and the levels of high-density lipoprotein cholesterol(HDL-C)and apoliprotein AI(APOAI)were significantly lower than those in the control group(P<0.05).In female CAD patients,the rs266729 polymorphism was significantly associated with CAD severity,and Gensini scores significantly increased with the increase of G allele.In the patients with diabetes mellitus and CAD,the correlation between the rs266729 polymorphism and CAD severity was close to statistical significance(P=0.058).In male CAD patients,body mass index(BMI)of the G allele carriers of the rs266729 polymorphism was significantly higher than that of CC genotype patients(P<0.05).Meta analysis showed that G allele of the rs266729 polymorphism significantly reduced the plasma levels of APN and HDL-C,increased the levels of BMI and triglyceride(TG)in females,and the differences were statistically significant(P<0.05).In male CAD patients,the patients with GG genotype of the rs2241766 polymorphism had significantly higher levels of VLDL-C than that of T allele carriers(P<0.05).In the non-diabetic control group,the subjects with GG genotype of the rs2241766 polymorphism had significantly higher levels of VLDL-C than that of TT genotype subjects(P<0.05),and the subjects with CT genotype of the rs2241766 polymorphism had significantly higher levels of hs-CRP than that of CC and TT genotype subjects(P<0.05).In this study,no significant differences in genotype and allele frequencies were observed between CAD group and control group(P>0.05).Conclusions:The rs266729 polymorphism in the promoter region of APN gene is significantly associated with the severity of CAD.In female and diabetic patients,G allele can significantly increase the severity of CAD,which may be mediated by the decrease of APN levels and dyslipidemia.The rs2241766 polymorphism is not associated with susceptibility and severity of CAD in the present study. |
